CCL8 and immunoglobulin G4-related sclerosing disease: In fact, anti-CCL8 Ab improved both the inflammation and the fibrosis of SGs in LAT mice, suggesting that inhibition of the hCCL18 (mCCL8)–CCR8 axis should shed light on new therapies for IgG4-RD.